The antitumor effects of vaccine-activated CD8 + T cells associate with weak TCR signaling and induction of stem-like memory T cells

Sha Wu, Wei Zhu, Yibing Peng, Lan Wang, Yuan Hong, Lei Huang, Dayong Dong, Junping Xie, Todd David Merchen, Edward James Kruse, Zong Sheng Guo, David Bartlett, Ning Fu, Yukai He

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To understand why vaccine-activated tumor-specific T cells often fail to generate antitumor effects, we studied two a-feto-protein–specific CD8 + T cells (Tet 499 and Tet 212 ) that had different antitumor effects. We found that Tet 499 required high antigen doses for reactivation, but could survive persistent antigen stimulation and maintain their effector functions. In contrast, Tet 212 had a low threshold of reactivation, but underwent exhaustion and apoptosis in the presence of persistent antigen. In vivo, Tet 499 cells expanded more than Tet 212 upon reencountering antigen and generated stronger antitumor effects. The different antigen responsiveness and antitumor effects of Tet 212 and Tet 499 cells correlated with their activation and differentiation states. Compared with Tet 212 , the population of Tet 499 cells was less activated and contained more stem-like memory T cells (Tscm) that could undergo expansion in vivo. The TCR signaling strength on Tet 499 was weaker than Tet 212 , correlating with more severe Tet 499 TCR downregulation. Weak TCR signaling may halt T-cell differentiation at the Tscm stage during immune priming and also explains why Tet 499 reactivation requires a high antigen dose. Weak TCR signaling of Tet 499 cells in the effector stage will also protect them from exhaustion and apoptosis when they reencounter persistent antigen in tumor lesion, which generates antitumor effects. Further investigation of TCR downregulation and manipulation of TCR signaling strength may help design cancer vaccines to elicit a mix of tumor-specific CD8 + T cells, including Tscm, capable of surviving antigen restimulation to generate antitumor effects.

Original languageEnglish (US)
Pages (from-to)908-919
Number of pages12
JournalCancer Immunology Research
Volume5
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Vaccines
T-Lymphocytes
Antigens
Cancer Vaccines
Down-Regulation
Apoptosis
Neoplasm Antigens
Cell Differentiation
Population
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

The antitumor effects of vaccine-activated CD8 + T cells associate with weak TCR signaling and induction of stem-like memory T cells . / Wu, Sha; Zhu, Wei; Peng, Yibing; Wang, Lan; Hong, Yuan; Huang, Lei; Dong, Dayong; Xie, Junping; Merchen, Todd David; Kruse, Edward James; Guo, Zong Sheng; Bartlett, David; Fu, Ning; He, Yukai.

In: Cancer Immunology Research, Vol. 5, No. 10, 01.10.2017, p. 908-919.

Research output: Contribution to journalArticle

Wu, Sha ; Zhu, Wei ; Peng, Yibing ; Wang, Lan ; Hong, Yuan ; Huang, Lei ; Dong, Dayong ; Xie, Junping ; Merchen, Todd David ; Kruse, Edward James ; Guo, Zong Sheng ; Bartlett, David ; Fu, Ning ; He, Yukai. / The antitumor effects of vaccine-activated CD8 + T cells associate with weak TCR signaling and induction of stem-like memory T cells In: Cancer Immunology Research. 2017 ; Vol. 5, No. 10. pp. 908-919.
@article{c8fb28c082f7426f9088684cb2c6a279,
title = "The antitumor effects of vaccine-activated CD8 + T cells associate with weak TCR signaling and induction of stem-like memory T cells",
abstract = "To understand why vaccine-activated tumor-specific T cells often fail to generate antitumor effects, we studied two a-feto-protein–specific CD8 + T cells (Tet 499 and Tet 212 ) that had different antitumor effects. We found that Tet 499 required high antigen doses for reactivation, but could survive persistent antigen stimulation and maintain their effector functions. In contrast, Tet 212 had a low threshold of reactivation, but underwent exhaustion and apoptosis in the presence of persistent antigen. In vivo, Tet 499 cells expanded more than Tet 212 upon reencountering antigen and generated stronger antitumor effects. The different antigen responsiveness and antitumor effects of Tet 212 and Tet 499 cells correlated with their activation and differentiation states. Compared with Tet 212 , the population of Tet 499 cells was less activated and contained more stem-like memory T cells (Tscm) that could undergo expansion in vivo. The TCR signaling strength on Tet 499 was weaker than Tet 212 , correlating with more severe Tet 499 TCR downregulation. Weak TCR signaling may halt T-cell differentiation at the Tscm stage during immune priming and also explains why Tet 499 reactivation requires a high antigen dose. Weak TCR signaling of Tet 499 cells in the effector stage will also protect them from exhaustion and apoptosis when they reencounter persistent antigen in tumor lesion, which generates antitumor effects. Further investigation of TCR downregulation and manipulation of TCR signaling strength may help design cancer vaccines to elicit a mix of tumor-specific CD8 + T cells, including Tscm, capable of surviving antigen restimulation to generate antitumor effects.",
author = "Sha Wu and Wei Zhu and Yibing Peng and Lan Wang and Yuan Hong and Lei Huang and Dayong Dong and Junping Xie and Merchen, {Todd David} and Kruse, {Edward James} and Guo, {Zong Sheng} and David Bartlett and Ning Fu and Yukai He",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/2326-6066.CIR-17-0016",
language = "English (US)",
volume = "5",
pages = "908--919",
journal = "Cancer Immunity",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - The antitumor effects of vaccine-activated CD8 + T cells associate with weak TCR signaling and induction of stem-like memory T cells

AU - Wu, Sha

AU - Zhu, Wei

AU - Peng, Yibing

AU - Wang, Lan

AU - Hong, Yuan

AU - Huang, Lei

AU - Dong, Dayong

AU - Xie, Junping

AU - Merchen, Todd David

AU - Kruse, Edward James

AU - Guo, Zong Sheng

AU - Bartlett, David

AU - Fu, Ning

AU - He, Yukai

PY - 2017/10/1

Y1 - 2017/10/1

N2 - To understand why vaccine-activated tumor-specific T cells often fail to generate antitumor effects, we studied two a-feto-protein–specific CD8 + T cells (Tet 499 and Tet 212 ) that had different antitumor effects. We found that Tet 499 required high antigen doses for reactivation, but could survive persistent antigen stimulation and maintain their effector functions. In contrast, Tet 212 had a low threshold of reactivation, but underwent exhaustion and apoptosis in the presence of persistent antigen. In vivo, Tet 499 cells expanded more than Tet 212 upon reencountering antigen and generated stronger antitumor effects. The different antigen responsiveness and antitumor effects of Tet 212 and Tet 499 cells correlated with their activation and differentiation states. Compared with Tet 212 , the population of Tet 499 cells was less activated and contained more stem-like memory T cells (Tscm) that could undergo expansion in vivo. The TCR signaling strength on Tet 499 was weaker than Tet 212 , correlating with more severe Tet 499 TCR downregulation. Weak TCR signaling may halt T-cell differentiation at the Tscm stage during immune priming and also explains why Tet 499 reactivation requires a high antigen dose. Weak TCR signaling of Tet 499 cells in the effector stage will also protect them from exhaustion and apoptosis when they reencounter persistent antigen in tumor lesion, which generates antitumor effects. Further investigation of TCR downregulation and manipulation of TCR signaling strength may help design cancer vaccines to elicit a mix of tumor-specific CD8 + T cells, including Tscm, capable of surviving antigen restimulation to generate antitumor effects.

AB - To understand why vaccine-activated tumor-specific T cells often fail to generate antitumor effects, we studied two a-feto-protein–specific CD8 + T cells (Tet 499 and Tet 212 ) that had different antitumor effects. We found that Tet 499 required high antigen doses for reactivation, but could survive persistent antigen stimulation and maintain their effector functions. In contrast, Tet 212 had a low threshold of reactivation, but underwent exhaustion and apoptosis in the presence of persistent antigen. In vivo, Tet 499 cells expanded more than Tet 212 upon reencountering antigen and generated stronger antitumor effects. The different antigen responsiveness and antitumor effects of Tet 212 and Tet 499 cells correlated with their activation and differentiation states. Compared with Tet 212 , the population of Tet 499 cells was less activated and contained more stem-like memory T cells (Tscm) that could undergo expansion in vivo. The TCR signaling strength on Tet 499 was weaker than Tet 212 , correlating with more severe Tet 499 TCR downregulation. Weak TCR signaling may halt T-cell differentiation at the Tscm stage during immune priming and also explains why Tet 499 reactivation requires a high antigen dose. Weak TCR signaling of Tet 499 cells in the effector stage will also protect them from exhaustion and apoptosis when they reencounter persistent antigen in tumor lesion, which generates antitumor effects. Further investigation of TCR downregulation and manipulation of TCR signaling strength may help design cancer vaccines to elicit a mix of tumor-specific CD8 + T cells, including Tscm, capable of surviving antigen restimulation to generate antitumor effects.

UR - http://www.scopus.com/inward/record.url?scp=85030700008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030700008&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-17-0016

DO - 10.1158/2326-6066.CIR-17-0016

M3 - Article

C2 - 28851693

AN - SCOPUS:85030700008

VL - 5

SP - 908

EP - 919

JO - Cancer Immunity

JF - Cancer Immunity

SN - 2326-6066

IS - 10

ER -